LicianPro

Acumen Pharmaceuticals, Inc. ·

ABOS 8-K 2026-09-16

Acumen Pharmaceuticals, Inc. (ABOS) 8-K dated 2026-09-16 — accession 0001628280-26-062137.

Acumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company listed on US.

Acumen Pharmaceuticals, Inc. filed a 8-K on 2026-09-16. Accession 0001628280-26-062137.

This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ABOS revenue for 2023-12-31 was $10.8M. Net income was -$52.4M. Revenue was up 351.1% from 2022-12-31 to 2023-12-31. ABOS currently screens at market cap $73.3M.

Not investment advice. The ABOS SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr